Digital therapy trials for dementia are research studies testing computer-based or mobile applications designed to slow cognitive decline, improve memory, or enhance quality of life in people with dementia. These trials represent a significant shift in how researchers approach dementia treatment—moving beyond pills alone to include interactive programs that patients can use at home, often independently or with caregiver support. A study conducted at Stanford University in 2023, for example, tested a tablet-based cognitive training program with 180 participants with mild cognitive impairment and early Alzheimer’s disease, measuring whether regular use of word games and spatial puzzles could preserve cognitive function over six months compared to a control group.
The rise of digital therapy trials reflects both technological capability and the practical reality of dementia care. Traditional cognitive interventions—like one-on-one speech therapy or neuropsychological testing—are expensive, geographically limited, and often unavailable in rural areas. Digital tools can reach more people, provide data on engagement and progress, and reduce the burden on overstretched healthcare systems. However, these trials are not a substitute for medical care or professional supervision; they are designed to complement existing dementia treatments and to answer fundamental questions about whether digital engagement can meaningfully affect the disease’s progression.
Table of Contents
- What Types of Digital Therapies Are Researchers Testing?
- What Does Current Trial Evidence Show?
- How Do Digital Trials Differ from Traditional Dementia Care?
- Who Can Participate in Digital Therapy Trials, and What Are the Practical Requirements?
- What Technical and Safety Issues Affect Digital Dementia Trials?
- How Do Families Find and Enroll in Digital Dementia Therapy Trials?
- Real-World Implementation and the Role of Caregivers in Digital Trials
What Types of Digital Therapies Are Researchers Testing?
Researchers are testing several categories of digital therapy in dementia trials. Cognitive training programs—which include memory games, attention exercises, and language tasks—are the most common. Examples range from custom software designed specifically for research (like the Stanford study’s puzzle platform) to adapted versions of commercially available brain-training apps like Lumosity and CogniFit, which have been modified for older adults with declining abilities.
Reminiscence therapy apps present photos, music, and videos from a person’s past, designed to trigger memories and emotional engagement; one UK trial tested an app that connected residents in care homes with digitized personal archives and found that participants showed improved mood and reduced agitation. Beyond cognitive games, trials are also testing digital platforms for social connection—video call groups, virtual reality environments, and online communities designed specifically for people with early-stage dementia who can still communicate clearly. A 2022 trial in Australia used a custom social platform where participants with mild dementia attended weekly virtual groups facilitated by a trained coordinator, with the hypothesis that structured social engagement might slow cognitive decline and reduce depression. Some trials combine physical activity monitoring with digital coaching; wearable devices track movement, and an app provides reminders and encouragement to walk or exercise, since physical activity is known to slow cognitive decline in dementia.
What Does Current Trial Evidence Show?
The evidence from digital therapy trials is mixed, which is important for families and patients to understand realistically. Some trials show modest benefits—typically a slowing of cognitive decline over 6 to 12 months, rather than improvement or reversal. A meta-analysis of cognitive training trials published in Neuropsychology Review in 2023 found that digital cognitive training produced small but measurable improvements in memory and processing speed for people with mild cognitive impairment, but the benefits did not consistently transfer to everyday functioning or prevent progression to dementia. More concerning, some trials have shown no difference between participants who used the app and control groups who received standard care or even a placebo app.
The quality of evidence varies dramatically across trials. Many studies have small sample sizes (fewer than 100 participants), short follow-up periods (6 months rather than 2 years), and high dropout rates—people with dementia often find digital interfaces frustrating and discontinue use. Additionally, trial participants tend to be younger, more educated, and more comfortable with technology than the broader dementia population, making results difficult to generalize. A major limitation is the “healthy adherer” problem: people who are motivated enough to consistently use a digital therapy app may be more likely to maintain cognitive health anyway, regardless of the app. Randomized controlled trials attempt to account for this, but real-world conditions are messier, and many people with dementia simply do not have the sustained attention or motivation to use an app several times per week for months.
How Do Digital Trials Differ from Traditional Dementia Care?
Digital therapy trials represent a fundamentally different model of measurement and engagement compared to standard clinical dementia care. In traditional settings, a neurologist or geriatrician sees a patient every 3 to 6 months, administers a brief cognitive test (like the Mini-Cog or Montreal Cognitive Assessment), and documents whether decline appears stable or progressive. A digital trial, by contrast, often collects data continuously or weekly—tracking how many times a person opened the app, how long they spent on tasks, error rates, and response times. This granular data can reveal changes in cognition that might not be apparent in a quarterly clinic visit. However, this continuous measurement also introduces new complications.
People may be less engaged when they know they are being measured, or conversely, they may perform differently depending on time of day, mood, medication side effects, or caregiver presence. A participant might complete a memory game perfectly one week and perform poorly the next week not because cognition has declined but because they had a poor sleep the night before or their arthritis is flaring, making fine motor control difficult. Additionally, digital interventions often lack the human connection that traditional therapy provides. A speech therapist or occupational therapist can adapt their approach based on emotional cues, offer encouragement, and address motivation—something a pre-programmed app cannot do. Some trials attempt to address this limitation by pairing the app with periodic coaching calls, but this added human contact then becomes a confounding variable that makes it unclear whether benefits came from the app or from social engagement with a coach.
Who Can Participate in Digital Therapy Trials, and What Are the Practical Requirements?
Most digital therapy trials for dementia enroll people with mild cognitive impairment or early-stage (mild to moderate) dementia who still have sufficient cognition to use a tablet or computer with or without caregiver assistance. Trials typically exclude people with advanced dementia, severe vision or hearing loss, or significant motor impairment. Age requirements vary—some trials focus on older adults (65+) while others enroll younger-onset dementia patients. Participants generally need regular internet access, either through home broadband or a device provided by the trial, and they must commit to a specific schedule, often several sessions per week for 6 to 12 months. The practical barrier for many families is the caregiver requirement.
Even “independent” digital therapy often requires a caregiver or family member to set up the technology, remind the person to use it, troubleshoot when the device crashes, and monitor adherence. For someone living alone or whose family members live far away, this is a significant obstacle. Trials that enroll people in assisted living or nursing homes fare better because staff can facilitate use, but this creates a selection bias—the trial results may not apply to community-dwelling older adults who have less structured support. Additionally, several trials have found that caregiver burden increases when the person with dementia is in a trial, because the caregiver must track usage, attend appointments, and manage the additional cognitive load of participating in research. This is rarely discussed in informed consent forms or trial materials, but it is a real cost to families.
What Technical and Safety Issues Affect Digital Dementia Trials?
A significant challenge in digital therapy trials is technology literacy and interface design. Many older adults, particularly those with dementia, have limited experience with tablets or computers. They may accidentally close the app, lose track of where they are in a task, or struggle with passwords and login screens. Trials have attempted to simplify interfaces—using large buttons, high-contrast text, and minimal menus—but even modest complexity can be a barrier. Some participants develop learned helplessness, where repeated failures to navigate the app lead them to give up, reducing engagement and biasing trial results toward people who are naturally more tech-savvy.
Data privacy and security are also serious concerns. Digital therapy trials collect detailed information about a person’s cognitive performance, usage patterns, location (if the app tracks this), and sometimes personal information shared in open-text fields. Healthcare companies and research institutions have varying standards for protecting this data, and data breaches targeting older adult health information are not uncommon. Participants should ask whether the trial has formal data security agreements, whether data is encrypted, and what happens to their data after the trial ends. Additionally, some commercial apps in trials are owned by private companies that may eventually use the trial data to develop products for marketing purposes, raising ethical questions that are not always transparent to participants at the time of enrollment.
How Do Families Find and Enroll in Digital Dementia Therapy Trials?
The primary resource for finding clinical trials in the United States is ClinicalTrials.gov, a government database maintained by the National Institutes of Health. Families can search for trials by condition (“dementia” or “mild cognitive impairment”), intervention type (“digital” or “app”), and location. The Alzheimer’s Association website also maintains a trial finder specific to dementia research.
Many university medical centers and research hospitals recruit through their neurology or gerontology clinics, and some trials send recruitment materials directly to patients already in the healthcare system. Support groups and dementia-focused nonprofits sometimes share information about local trials recruiting. When evaluating whether to enroll, families should ask the trial team for clarification on several points: What is the specific hypothesis being tested? What are the time commitments and frequency of visits or app use? What are the potential risks or side effects, and what happens if the person becomes unable to continue due to disease progression? Are there payments or reimbursement for participation? What are the qualifications and availability of the trial staff for troubleshooting? A trial that sounds promising on paper may be poorly executed in practice, so talking directly with current or former participants, if available, can provide valuable insight.
Real-World Implementation and the Role of Caregivers in Digital Trials
In practice, digital therapy trials work best when caregivers are actively involved, yet many trials design their primary outcomes around the person with dementia alone. A caregiver might spend 30 minutes per session helping set up the app, staying present while the person completes tasks, troubleshooting technical problems, and recording data—while the trial measures only the person with dementia’s cognitive scores. This unpaid labor is rarely acknowledged or accommodated in trial design. Some well-designed trials now include the caregiver in the intervention itself, recognizing that caregiver stress and depression can affect a person with dementia’s participation and outcomes.
A trial at Johns Hopkins that provided both digital cognitive training to the person with dementia and a parallel digital support program for caregivers found higher engagement and better mood outcomes for both groups compared to cognitive training alone. The long-term question that trials are still struggling to answer is durability—does benefit persist after the trial ends? Many cognitive training studies show that improvements disappear within months of stopping the intervention, suggesting that the person must continue using the app indefinitely to maintain any benefit. For a person with progressive dementia, this may become impossible as their disease worsens and they lose the ability or motivation to engage with technology. This reality tempers enthusiasm about digital therapies as disease-modifying interventions and suggests they are best viewed as tools to maintain quality of life and engagement during the early stages of cognitive decline, rather than as cures or powerful reversals of dementia’s course.
- —
